Gene · 5771
Papers2,250
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 2,250
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Protein tyrosine phosphatase non-receptor II: A possible biomarker of poor prognosis and mediator of immune evasion in hepatocellular carcinoma. | World J Gastrointest Oncol | 2024 | 39350977 | PubTator, text mining | PubMed |
| Lanostane triterpenoids from Ganoderma calidophilum exhibit potent anti-tumor activity by inhibiting PTP1B. | Chem Biol Interact | 2024 | 39341486 | PubTator, text mining | PubMed |
| Protein tyrosine phosphatase non-receptor type 2 (PTPN2) gene polymorphisms (rs2542151, rs7234029) in Egyptian Behçet's disease patients: a preliminary report. | Clin Rheumatol | 2024 | 39320556 | PubTator, text mining | PubMed |
| ETHE1 dampens colorectal cancer angiogenesis by promoting TC45 Dephosphorylation of STAT3 to inhibit VEGF-A expression. | Cell Death Dis | 2024 | 39198402 | PubTator, text mining | PubMed |
| Mapping spatial organization and genetic cell-state regulators to target immune evasion in ovarian cancer. | Nat Immunol | 2024 | 39179931 | PubTator, text mining | PubMed |
| Regulation of protein phosphorylation by PTPN2 and its small-molecule inhibitors/degraders as a potential disease treatment strategy. | Eur J Med Chem | 2024 | 39178726 | PubTator, text mining | PubMed |
| Enhancing the apo protein tyrosine phosphatase non-receptor type 2 crystal soaking strategy through inhibitor-accessible binding sites. | Acta Crystallogr F Struct Biol Commun | 2024 | 39177701 | PubTator, text mining | PubMed |
| Mechanistic insights into a heterobifunctional degrader-induced PTPN2/N1 complex. | Commun Chem | 2024 | 39152201 | PubTator, text mining | PubMed |
| PTPN2 copper-sensing relays copper level fluctuations into EGFR/CREB activation and associated CTR1 transcriptional repression. | Nat Commun | 2024 | 39138174 | PubTator, text mining | PubMed |
| The HIV latency reversing agent HODHBt inhibits the phosphatases PTPN1 and PTPN2. | JCI Insight | 2024 | 39115957 | PubTator, text mining | PubMed |
| 3-Benzylaminomethyl Lithocholic Acid Derivatives Exhibited Potent and Selective Uncompetitive Inhibitory Activity Against Protein Tyrosine Phosphatase 1B (PTP1B). | ACS Omega | 2024 | 39100322 | PubTator, text mining | PubMed |
| PTPN2 deficiency: Amping up JAK/STAT. | J Exp Med | 2024 | 39028870 | PubTator, text mining | PubMed |
| Haploinsufficiency in PTPN2 leads to early-onset systemic autoimmunity from Evans syndrome to lupus. | J Exp Med | 2024 | 39028869 | PubTator, text mining | PubMed |
| Ilexgenin A inhibits lipid accumulation in macrophages and reduces the progression of atherosclerosis through PTPN2/ERK1/2/ABCA1 signalling pathway. | Biochim Biophys Acta Mol Cell Biol Lipids | 2024 | 39009241 | PubTator, text mining | PubMed |
| Tumor microenvironment responsive nano-herb and CRISPR delivery system for synergistic chemotherapy and immunotherapy. | J Nanobiotechnology | 2024 | 38898493 | PubTator, text mining | PubMed |
| Alteration of circulating ACE2-network related microRNAs in patients with COVID-19. | Sci Rep | 2024 | 38866792 | PubTator, text mining | PubMed |
| Little ones can do big things: Small molecule inhibitors target PTPN2/PTPN1 for tumor immunotherapy. | MedComm (2020) | 2024 | 38817652 | PubTator, text mining | PubMed |
| Stability mapping of bipartite tight-binding graphs with losses and gain: PTPT-symmetry and beyond. | Chaos | 2024 | 38717412 | PubTator, text mining | PubMed |
| Immunotherapeutic implications of negative regulation by protein tyrosine phosphatases in T cells: the emerging cases of PTP1B and TCPTP. | Front Med (Lausanne) | 2024 | 38707187 | PubTator, text mining | PubMed |
| Prenylated indole diketopiperazine alkaloids as phosphatase inhibitors from the marine-derived fungus Talaromyces purpureogenus. | Phytochemistry | 2024 | 38705266 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5771/papers?page=6